{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:48:39Z","timestamp":1724478519324},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T00:00:00Z","timestamp":1468108800000},"content-version":"vor","delay-in-days":191,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["idcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/j.idcr.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T07:57:49Z","timestamp":1470988669000},"page":"83-84","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cytomegalic hepatitis in a patient receiving omalizumab"],"prefix":"10.1016","volume":"5","author":[{"given":"R.","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Saraiva","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2016.08.001_bib0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Micro Rev"},{"key":"10.1016\/j.idcr.2016.08.001_bib0010","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cis818","article-title":"State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician","volume":"55","author":"Egli","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2016.08.001_bib0015","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1600-6143.2008.02191.x","article-title":"Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation","volume":"8","author":"Mattes","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idcr.2016.08.001_bib0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2016.08.001_bib0025","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ajt.13012","article-title":"Factors related to the development of CMV-specific CD8\u00fe T cell response in CMV seropositive solid organ transplant candidates","volume":"15","author":"Cantis\u00e1n","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idcr.2016.08.001_bib0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/CVI.00372-09","article-title":"Comparison of three automated immunoassay methods for the determination of Epstein-Barr virus-specific immunoglobulin M","volume":"17","author":"Berth","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"31","key":"10.1016\/j.idcr.2016.08.001_bib0035","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/JCM.31.5.1339-1341.1993","article-title":"Evaluation of five enzyme immunoassays for detection of immunoglobulin M antibodies to Epstein-Barr virus viral capsid antigens","volume":"1993","author":"Wiedbrauk","year":"1993","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0166-0934(95)01971-5","article-title":"Evaluation of 11 enzyme immunoassays for the detection of immunoglobulin M antibodies to Epstein-Barr virus","volume":"57","author":"Weber","year":"1996","journal-title":"J Virol Methods"},{"key":"10.1016\/j.idcr.2016.08.001_bib0045","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/jmv.10439","article-title":"Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection","volume":"70","author":"Robertson","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000441-197811000-00010","article-title":"Infectious mononucleosis and related syndromes","volume":"276","author":"Evans","year":"1978","journal-title":"Am J Med Sci"},{"issue":"December (138)","key":"10.1016\/j.idcr.2016.08.001_bib0055","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1183\/16000617.00001715","article-title":"Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives","volume":"24","author":"Samitas","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.idcr.2016.08.001_bib0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/72601","article-title":"The pharmacological basis of anti-IgE therapy","volume":"18","author":"Chang","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0065","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaci.2006.04.005","article-title":"Anti-IgE as a mast cell-stabilizing therapeutic agent","volume":"117","author":"Chang","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(06)93002-8","article-title":"Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases","volume":"93","author":"Chang","year":"2007","journal-title":"Adv Immunol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaci.2008.10.053","article-title":"Therapeutic efficacy of omalizumab","volume":"123","author":"MacGlashan","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0080","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0085","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaci.2012.05.038","article-title":"Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors","volume":"130","author":"MacGlashan","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.idcr.2016.08.001_bib0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250916300580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250916300580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T17:03:57Z","timestamp":1692464637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250916300580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":19,"alternative-id":["S2214250916300580"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2016.08.001","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalic hepatitis in a patient receiving omalizumab","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}